Lymphoma Research Foundation Funds Blood Cancer Research in Critical Disease-Specific Focus Areas

Share Article

Grants to Support Research of Burkitt’s, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-cell and Adult T-cell Lymphomas

News Image

The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted to funding innovative lymphoma research – is pleased to announce that it has awarded nearly one million dollars in grants to eight scientists investigating new treatments for lymphoma. The grants provide support for projects aimed at gaining a better understanding of Burkitt’s, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell and adult T-cell lymphomas.

“Since its inception, the Lymphoma Research Foundation has placed great emphasis on attracting the best and brightest scientists to the field of lymphoma research and to training the next generation of lymphoma investigators,” said Diane Blum, LRF Chief Executive Officer. “We are honored to be able to award nearly one million dollars in lymphoma research and remain grateful for our supporters whose generosity enables the Foundation to continue its investment in innovative research.”

Recommendations for research funding were made by the LRF Scientific Advisory Board, which is comprised of the world’s leading lymphoma researchers and oncologists. The award recommendations were then approved by the LRF Board of Directors. Grantees include:

Clinical Investigator Career Development Award ($225,000 per award over three years)

Farrukh Awan, MD
Georgia Health Sciences University Research Institute
A PK/PD based phase I/II clinical trial of a novel IDO inhibitor (1-MT) in patients with CLL/SLL
Supported by funding from Genentech

Post Doctoral Fellowship Awards ($105,000 per award over two years)

Hicham Hachem Baydoun, PhD
Washington University in St. Louis
Role of nitric oxide in the leukemogenesis associated with adult T-cell leukemia/lymphoma

Lorena Fontan, PhD
Joan & Sanford I. Weill Medical College of Cornell University
Therapeutic targeting of diffuse large B-cell lymphomas by MALT1 inhibition
Supported by funding from Millennium: The Takeda Oncology Company

Javeed Iqbal, PhD
University of Nebraska of Nebraska Medical Center
Mutations in the pathogenesis of angioimmunoblastic T-cell lymphoma

Samantha Kendrick, PhD
Arizona Board of Regents, University of Arizona
Targeting chemotherapy resistance in diffuse large B-cell lymphoma
Supported by funding from Genentech

Lisa Giulino Roth, MD
Joan & Sanford I. Weill Medical College of Cornell University
Evaluation of MCL1 as a therapeutic target in Burkitt lymphoma
Supported by funding from Millennium: The Takeda Oncology Company

Yusuke Shono, MD, PhD
Sloan-Kettering Institute for Cancer Research
A novel method for graft-versus-host disease prophylaxis without compromising tumor immunity

Lili Wang, MD
Dana Farber Cancer Institute
Dissecting the functional impact of mutated SF3B1 on CLL/SLL
Supported by funding from Millennium: The Takeda Oncology Company

“Through its Clinical Career Development Awards and Post Doctoral Fellowships, the Lymphoma Research Foundation is able to identify and invest in future research leaders who will advance our understanding of the disease and discover unique approaches for treating lymphoma,” said Dr. John P. Leonard, Chair of LRF’s Scientific Advisory Board, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Associate Dean for Clinical Research at Weill Cornell Medical College. “My colleagues and I on the Foundation’s Scientific Advisory Board are pleased to recommend funding for these promising research projects and look forward to awarding more grants in the coming year.”

For more information about lymphoma or the Foundation’s research portfolio, visit the LRF website:

About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded more than $51 million in lymphoma-specific research.

For additional information on LRF’s research, education and services, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peggy Ann Torney
Follow us on
Visit website